Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia

Pennell, Dudley J., Porter, John B., Cappellini, Maria Domenica, El-Beshlawy, Amal, Chan, Lee Lee, Aydinok, Yesim, Elalfy, Mohsen Saleh, Sutcharitchan, Pranee, Li, Chi-Kong, Ibrahim, Hishamshah, Viprakasit, Vip, Kattamis, Antonis, Smith, Gillian, Habr, Dany, Domokos, Gabor, Roubert, Bernard, Taher, Ali · 2010 · Blood

Abstract

Cardiac iron overload causes most deaths in β-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac iron overload was assessed in 192 patients with β-thalassemia in a 1-year prospective, multicenter study. The cardiac iron reduction arm (n = 114) included patients with magnetic resonance myocardial T2* from 5 to 20 ms (indicating cardiac siderosis), left ventricular ejection fraction (LVEF) of 56% or more, serum ferritin more than 2500 ng/mL, liver iron concentration more than 10 mg Fe/g dry weight, and more than 50 transfused blood units. The prevention arm (n = 78) included otherwise eligible patients whose myocardial T2* was 20 ms or more. The primary end point was the change in myocardial T2* at 1 year. In the cardiac iron reduction arm, the mean deferasirox dose was 32.6 mg/kg per day. Myocardial T2* (geometric mean ± coefficient of variation) improved from a baseline of 11.2 ms (± 40.5%) to 12.9 ms (± 49.5%) (+16%; P < .001). LVEF (mean ± SD) was unchanged: 67.4 (± 5.7%) to 67.0 (± 6.0%) (−0.3%; P = .53). In the prevention arm, baseline myocardial T2* was unchanged from baseline of 32.0 ms (± 25.6%) to 32.5 ms (± 25.1%) (+2%; P = .57) and LVEF increased from baseline 67.7 (± 4.7%) to 69.6 (± 4.5%) (+1.8%; P < .001). This prospective study shows that deferasirox is effective in removing and preventing myocardial iron accumulation. This study is registered at http://clinicaltrials.gov as NCT00171821.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-04-217455

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 195

Metadata

Authors
Pennell, D. J., Porter, J. B., Cappellini, M. D., El-Beshlawy, A., Chan, L. L., Aydinok, Y., Elalfy, M. S., Sutcharitchan, P., Li, C.-K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., & Taher, A.
Venue
Blood
Published
2010-03-25
Volume
115
Issue
12
Pages
2364-2371
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2076446665
Cited by
195
References
1
FWCI
10.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. https://app.cochat.ai/papers/10.1182/blood-2009-04-217455
The paper
Pennell, D. J., Porter, J. B., Cappellini, M. D., El-Beshlawy, A., Chan, L. L., Aydinok, Y., Elalfy, M. S., Sutcharitchan, P., Li, C.-K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., & Taher, A. (2010). Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. https://doi.org/10.1182/blood-2009-04-217455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.